Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib with Pemetrexed and Carboplatin in Osimertinib-resistant NSCLC
NCT04136535Phase 2Recruiting
- Sponsor
- Fudan University
- Start
- Nov 2021
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of anlotinib in non-small cell lung cancer (NSCLC), sponsored by Fudan University. Started Nov 2021; status: recruiting.
02
Drugs
anlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04136535.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04136535.